Atorvastatin improves systolic function, but does not prevent the development of dilated cardiomyopathy in streptozotocin-induced diabetic rats

Therapeutic Advances in Cardiovascular Disease

Volumn 8, Issue 4, 2014, Pages 133-144

  Quidgley, Jose ^a   Cruz, Nildris ^a   Crespo, Maria J ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

atorvastatin; cardiac function; cholesterol; endothelial function; oxidative stress; type 1 diabetic rats

Indexed keywords

ACETYLCHOLINE; ATORVASTATIN; CHOLESTEROL; MALONALDEHYDE; N(G) NITROARGININE METHYL ESTER; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EVALUATION STUDY; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE FIBROSIS; HEART OUTPUT; HEART PERFORMANCE; HEART STRESS; HEART STROKE VOLUME; HISTOPATHOLOGY; HOMOGENATE; LIPID PEROXIDATION; LOW DRUG DOSE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 84902509850     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944714531065     Document Type: Article

References (48)

1. Adameova A. Harcarova A. Matejikova J. Pancza D. Kuzelova M. Carnicka S. et al. (2009) Simvastatin alleviates myocardial contractile dysfunction and lethal ischemic injury in rat heart independent of cholesterol-lowering effects. Physiol Res 58: 449–454.
2. Ali T. Al-Gayyar M. Matragoon S. Pillai B. Abdelsaid M. Nussbaum J. et al. (2011) Diabetes-induced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury. Diabetologia 54: 657–668.
3. American Diabetes Association (2013) Standards of medical care in diabetes 2013. Diabetes Care 36(Suppl. 1): S11–S66.
4. Bleske B. Willis R. Anthony M. Casselberry N. Datwani M. Uhley V. et al. (2001) The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J 142: e2.
5. Caso G. Kelly P. McNurlan M. Lawson W. (2007) Effect of coenzyme Q 10 on myopathic symptoms in patients treated with statins. Am J Cardiol 99: 1409–1412.
6. Chen Y. Ohmori K. Mizukawa M. Yoshida J. Zeng Y. Zhang L. et al. (2007) Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J 71: 144–152.
7. Colhoun H. Betteridge D. Durrington P. Hitman G. Neil H. Livingstone S. et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo–controlled trial. Lancet 64: 685–696.
8. Cosentino F. Hishikawa K. Katusic Z. Lüscher T. (1997) High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 96: 25–28.
9. Crane F. (2001) Biochemical functions of coenzyme Q10. J Am Coll Nutr 20: 591–598.
10. Crespo M. Dunbar D. (2003) Enalapril improves vascular and cardiac function in STZ-diabetic rats. Mol Cell Biol 49: 1311–1318.
11. Crespo M. Marrero M. Cruz N. Quidgley J. Creagh O. Torres H. et al. (2011) Diabetes alters cardiovascular responses to anaesthetic induction agents in STZ-diabetic rats. Diab Vasc Dis Res 8: 299–302.
12. Crespo M. Moreta S. Gonzalez J. (2003) Cardiovascular deterioration in STZ-diabetic rats: possible role of vascular RAS. Pharmacology 68: 1–8.
13. Crespo M. Zalacaín J. Dunbar D. Cruz N. Arocho L. (2008) Cardiac oxidative stress is elevated at the onset of dilated cardiomyopathy in STZ-diabetic rats. J Cardiovasc Pharmacol Ther 13: 64–71.
14. de Pinieux G. Chariot P. Ammi-Saïd M. Louarn F. Lejonc J. Astier A. et al. (1996) Lipid–lowering drugs and mitochondrial function: effects of HMG–CoA reductase inhibitors on serum ubiquinone and blood lactate / pyruvate ratio. Br J Clin Pharmacol 42: 333–337.
15. Dogra G. Watts G. Chan D. Stanton K. (2005) Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria. Diabet Med 22: 239–242.
16. Elmadhun N. Lassaletta A. Chu L. Liu Y. Feng J. Sellke F. (2012) Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome. J Thorac Cardiovasc Surg 144: 1486–1493.
17. Forcillo J. Maltais S. Aubin M. Shi Y. Carrier M. Tardif J. et al. (2011) Atorvastatin worsens left ventricular diastolic dysfunction and endothelial dysfunction of epicardial coronary arteries in normocholesterolemic porcine with left ventricular hypertrophy. J Cardiovasc Pharmacol 58: 295–306.
18. Genuth S. Backlund J. Bayless M. Bluemke D. Cleary P. Crandall J. et al. (2013) Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC. Diabetes 62: 3561–3569.
19. Huang B. Li F. Wu C. Wang D. (2012) The role of nitric oxide on rosuvastatin-mediated S-nitrosylation and translational proteomes in human umbilical vein endothelial cells. Proteome Sci 10:43.
20. Ikeda Y. Martone M. Gu Y. Hoshijima M. Thor A. Oh S. et al. (2000) Altered membrane proteins and permeability correlate with cardiac dysfunction in cardiomyopathic hamsters. Am J Physiol Heart Circ Physiol 278: H1362–H1370.
21. Ito D. Ito O. Mori N. Muroya Y. Cao P. Takashima K. et al. (2010) Atorvastatin upregulates nitric oxide synthases with Rho–kinase inhibition and Akt activation in the kidney of spontaneously hypertensive rats. J Hypertens 28: 2278–2288.
22. Joffe I. Travers K. Perreault-Micale C. Hampton T. Katz S. Morgan J. et al. (1999) Abnormal cardiac function in the streptozotocin–induced non–insulin–dependent diabetic rat: noninvasive assessment with Doppler echocardiography and contribution of the nitric oxide pathway. J Am Coll Cardiol 34: 2111–2119.
23. Konduracka E. Galicka-Latala D. Cieslik G. Rostoff P. Fedak D. Sieradzki J. et al. (2008) Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension. Diabetes Obes Metab 10: 719–725.
24. Kosiborod M. Inzucchi S. Goyal A. Krumholz H. Masoudi F. Xiao L. et al. (2009) Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. J Am Med Assoc 30: 1556–1564.
25. Laufs U. La Fata V. Plutzky J. Liao J. (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129–1135.
26. Laaksonen R. Ojala J. Tikkanen M. Himberg J. (1994) Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 46: 313–317.
27. Lipinski M. Cauthen C. Biondi-Zoccai G. Abbate A. Vrtovec B. Khan B. et al. (2009) Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol 104: 1708–1716.
28. Mebazaa A. Gayat E. Lassus J. Meas T. Mueller C. Maggioni A. et al. (2013) Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. J Am Coll Cardiol 61: 820–829.
29. Morrish N. Wang S. Stevens L. Fuller J. Keen H. (2001) Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44: S14–S21.
30. Palmer A. Gopaul N. Dhir S. Thomas C. Poston L. Tribe R. (1998) Endothelial dysfunction in streptozotocin-diabetic rats is not reversed by dietary probucol or simvastatin supplementation. Diabetologia 41: 157–164.
31. Riad A. Du J. Stiehl S. Westermann D. Mohr Z. Sobirey M. et al. (2007) Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus. Eur J Pharmacol 569: 204–211.
32. Rundek T. Naini A. Sacco R. Coates K. DiMauro S. (2004) Atorvastatin decreases the coenzyme Q 10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 61: 889–892.
33. Santos K. Crispim D. Canani L. Ferrugem P. Gross J. Roisenberg I. (2012) Relationship of endothelial nitric oxide synthase (eNOS) gene polymorphisms with diabetic retinopathy in Caucasians with type 2 diabetes. Ophthalmic Genet 33: 23–27.
34. Schäfer A. Fraccarollo D. Eigenthaler M. Tas P. Firnschild A. Frantz S. et al. (2005) Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability. Arterioscler Thromb Vasc Biol 25: 1071–1077.
35. Shinohara K. Shoji T. Kimoto E. Yokoyama H. Fujiwara S. Hatsuda S. et al. (2005) Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb 12: 205–210.
36. Shinozaki T. Matsuyama Y. Iimuro S. Umegaki H. Sakurai T. Araki A. et al. (2012) Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model. Geriatr Gerontol Int 12(Suppl. 1): 88–102.
37. Sola S. Mir M. Lerakis S. Tandon N. Khan B. (2006) Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47: 332–337.
38. Tantikosoom W. Thinkhamrop B. Kiatchusakul S. Jarernsiripornkul N. Srinakarin J. Ojongpian S. (2005) Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level. J Med Assoc Thai 88:399–406.
39. Tavazzi L. Maggioni A. Marchioli R. Barlera S. Franzosi M. Latini R. et al. (2008) Effect of rosuvastatin in patients with chronic heart failure (the GISSI–HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372: 1231–1239.
40. van Leuven S. Kastelein J. (2005) Atorvastatin. Expert Opin Pharmacother 6: 1191–1203.
41. van Linthout S. Riad A. Dhayat N. Spillmann F. Du J. Dhayat S. et al. (2007) Anti–inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia 50: 1977–1986.
42. Wassmann S. Laufs U. Bäumer A. Müller K. Ahlbory K. Linz W. et al. (2001) HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37: 1450–1457.
43. Wassmann S. Laufs U. Müller K. Konkol C. Ahlbory K. Bäumer A. et al. (2002) Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22: 300–305.
44. Wenzel P. Daiber A. Oelze M. Brandt M. Closs E. Xu J. et al. (2008) Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis 198: 65–76.
45. Xie R. Cui W. Liu F. Yang C. Pei W. Lu J. et al. (2010) Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure. Int J Cardiol 140: 255–257.
46. Yamada T. Node K. Mine T. Morita T. Kioka H. Tsukamoto Y. et al. (2007) Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J 153: 1055.e1–1055.e8
47. Yamagishi S. Imaizumi T. (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Phar Des 11: 2279–2299.
48. Yamagishi S. Matsui T. Nakamura K. (2006) Atorvastatin and diabetic vascular complications. Curr Pharm Des 12 :1549–1554.